ACIP rec­om­mends rou­tine use of mpox vac­cine for at-risk adults, open­ing the door to po­ten­tial 2024 launch

The CDC’s Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices (ACIP) has vot­ed in fa­vor of rou­tine use of the mpox vac­cine Jyn­neos, open­ing the door to po­ten­tial com­mer­cial op­por­tu­ni­ties for its man­u­fac­tur­er.

Bavar­i­an Nordic re­port­ed “over­whelm­ing” in­ter­est in Jyn­neos amid the glob­al mpox out­break. The two-dose vac­cine was one of the on­ly in­ter­ven­tions avail­able and of­ten the pre­ferred one, though it was on­ly rec­om­mend­ed for at-risk in­di­vid­u­als dur­ing an out­break.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.